Latest news with #Activity
9 News
27-05-2025
- Business
- 9 News
Three jailed, 18 charged over millions in tax fraud
Your web browser is no longer supported. To improve your experience update it here Three people have been jailed for tax fraud offences while another 18 people have been charged over "a number of large-scale deceptions" of financial institutions and government agencies, Queensland Police and the ATO have said. Detectives allege the 18 individuals provided false details to receive fraudulent payments, defrauding the Australian Tax Office out of $2 million. The sting was part of a wider investigation with the ATO, which targeted offenders allegedly inventing fake businesses and submitting false Business Activity Statements to collect a GST refund. Generic photo of people walking out of the ATO Office. (AFR/ Luis Enrique Ascui) Three people were jailed as part of the operation. Queensland woman Tiarn Payten Nutley was found guilty of defrauding the ATO out of $50,000, and attempting to gain another $25,000. The ATO said she used an existing ABN to claim fraudulent GST refunds for a beauty and salon services business. She was sentenced to nine months in jail before she was released on a recognisance release order. She is required to be on good behaviour for a year. She had shared her MyGov log-in with two friends, who planned to lodge six false business activity statements (BAS) in her name. One of those friends, Skye Anne Hoek, was also sentenced over the tax fraud. Hoek lodged two BAS containing false information from Nutley's account, resulting in a $25,000 payday from GST refunds. She has been jailed for three months. It's alleged that the 18 individuals defrauded the Australian Tax Office out of $2 million. (Supplied) In a separate case, Queensland man Gregory Pimm lodged 37 BAS for a road freight transport business that didn't exist. Pimm claimed he ran the company from his home. He received over $165,000 in GST refunds and attempted to obtain another $300,000. The ATO said Pimm falsely reported total sales, GST collected on sales, GST on purchases made for the business and GST credits the ATO owed him. He was sentenced to 2 years and six months, but he will be released on recognisance of $500 after serving 6 months. Since the start of the investigation in 2022, officers have charged 84 people with defrauding the ATO out of over $8.5 million. ATO Acting Deputy Commissioner Kath Anderson said tax fraud was "not a victimless crime." "There are consequences for committing it," Anderson said. "These consequences can have a huge impact on your life, from employment, the ability to get a loan, to asset confiscation and ultimately jail time". Detective Senior Sergeant Brad Grace said Queensland police will continue cracking down on alleged tax fraud. "The Queensland Police Service (QPS) will continue to work closely with our government partners to identify and prosecute criminals who profit from defrauding the government," Grace said. "The cost of offending is large and has a real impact on the economy and community, the results would not have been possible without the assistance provided by the Australian Taxation Office." national police Tax crime Fraud queensland Brisbane CONTACT US Auto news: Google Gemini AI assistant coming to new cars in 2025.
Business Upturn
22-05-2025
- Business
- Business Upturn
Solidus Labs Unveils Agentic-Based Compliance: A New Model for Trade Surveillance Operations
By Business Wire Published on May 22, 2025, 17:38 IST New York, United States: Solidus Labs , the category-definer in trade surveillance and risk monitoring for digital and traditional asset classes, today announced the launch of Agentic-Based Compliance, a groundbreaking model for surveillance operations that leverages a network of AI agents to deliver exponential efficiency, precision, and intelligence across the entire trade surveillance and transaction monitoring investigation lifecycle. Legacy compliance solutions have failed to keep up with the rapid modernization and growing complexity of global markets. Compliance teams are forced to work with a patchwork of disconnected and expensive tools that fail to deliver results efficiently. According to McKinsey , compliance analysts spend 80% of their time on low or moderate-risk issues, often repetitively resolving false positives or performing menial work. This inefficiency extends to market abuse detection: Despite the enormous resources and efforts invested in compliance technology, firms continue to face enforcement actions for missed manipulation. Research shows that market abuse like insider trading occurs in 20% of mergers and acquisitions and 5% of quarterly earnings announcements in U.S. markets. More broadly, only 4% of Suspicious Activity Reports (SARs) lead to law enforcement investigations. This isn't a failure of effort – it's a failure of architecture. Built on Solidus' proprietary platform, HALO, Agentic-Based Compliance reimagines how financial institutions detect, investigate, and resolve market abuse risks. It replaces legacy systems and siloed workflows with a unified, intelligence-led architecture powered by autonomous AI agents that augment human analysts and operate across a multi-dimensional risk environment. 'Agentic-Based Compliance is the only way compliance teams can stay ahead of emerging complexities like 24/7 off-platform trading, enhanced retail participation and the heightened risks they carry for cyber-enhanced financial crimes and cross-product and cross-market manipulation,' said Asaf Meir, Founder and Chief Executive of Solidus Labs. 'Our vision is simple: Compliance operations should be as scalable, intelligent, and efficient as the markets they're designed to protect. Solidus' Agentic-Based Compliance delivers just that, solving for tech sprawl, alert fatigue, talent shortage and surveillance blind spots that cost firms thousands of hours and can reach billions of dollars in losses and fines.' HALO embeds a fleet of purpose-built AI agents, each designed to streamline a specific stage of the compliance investigation lifecycle — from signal enrichment and alert remediation to model testing, OSINT intelligence feeds, case management, and regulatory reporting. Born in crypto's highly fragmented and complex environment, Solidus' Agentic-Based Compliance is future-proof by design for all asset classes, leading to 20X faster investigations and saving compliance analysts as much as 5 hours of menial work per day. Like all Solidus Labs' solutions, it was developed in tandem with regulatory feedback – aligning with the current and evolving demands of modern financial markets, including the imperatives of market abuse regulations in the U.S., EU, and other leading jurisdictions. Poised to power the next generation of surveillance operations, Solidus' Agentic-Based Compliance is already gaining traction among forward-looking financial firms seeking to modernize their compliance capabilities and reduce operational strain. To learn more, visit . About Solidus Labs Solidus Labs is the category-definer for Agentic-Based Compliance in trade surveillance and risk monitoring. Founded in 2018 by Goldman Sachs veterans, the company merges Wall Street rigor, crypto-native innovation, and cybersecurity principles to reinvent compliance for the modern financial era. At the core is HALO, an AI-powered risk-based platform trusted by financial institutions, crypto firms, and regulators globally to drive proactive, intelligence-led oversight — across any product, venue, or asset class. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Business Wire is an American company that disseminates full-text press releases from thousands of companies and organizations worldwide to news media, financial markets, disclosure systems, investors, information web sites, databases, bloggers, social networks and other audiences.
Engadget
21-05-2025
- Health
- Engadget
Oura's smart ring gets better at tracking your activities
Oura has rolled out activity updates to its smart ring, including a new trend view for active minutes so that users can get a better look at how active they are for the day, the week or even the whole month. They'll also be able to add their max heart rate to the activity setting, and Oura will adjust heart rate zones accordingly. Oura now allows users to add or edit activities for the past seven days manually, instead of just for that particular day, and it now displays heart rate data from activities imported from partner integrations via Apple HealthKit and Health Connect by Android. Its Automatic Activity Detection feature has also been updated to work all hours to track movements, even for activities between midnight and 4AM. In addition to those new features, Oura has upgraded its system to be able to count steps more accurately. The company uses an advanced machine-learning model to determine whether a movement is an actual step, and it says the technology slashes average daily step count error by 61 percent. It has upgraded its Active Calorie burn feature to be more accurate by taking heart rate into account during exercise, as well. Oura can now also use your phone's GPS data to show your runs and walks in more detail within its app. All these updates are now available on iOS, but the new fitness metrics and new trend view for active minutes won't be out on Android until June. We've also pinged Oura to clarify which models are getting the updates. Aside from announcing its upgraded features, Oura has revealed its new partnerships with third-party entities. Users can now link their smart ring with CorePower Yoga so that they can track their yoga activities, Sculpt Society, Technogym and Open, which uses a person's biometrics to create personalized recovery rituals for them.
Leader Live
15-05-2025
- Leader Live
'Last chance' for Wrexham teenager found with ketamine
Yussif Saeed of Glaslyn, Plas Madoc in Acrefair, appeared before Mold Crown Court this afternoon (May 15). On February 24 of this year, the 18-year-old was handed a nine month term of detention in a young offenders institute, which was suspended for 12 months. That was for one offence of wounding which took place in Wrexham city centre. On April 14, he pleaded guilty in Wrexham Magistrates Court to one offence of being in possession of ketamine. Joseph Lees, prosecuting, explained that he also pleaded guilty to breaching his suspended sentence order. On February 26, at around 6pm, North Wales Police officers spotted Saeed at the King Street bus station in Wrexham, with two other individuals. They had decided to stop as they were aware that he had 'a history of violence', the prosecution said. Saeed was placed in handcuffs and searched. He admitted to officers that he has 'something in his pocket', which turned out to be a small quantity of ketamine. He told them he was 'addicted' to the drug and admitted to having taken some of it earlier in the day, despite being on his way to work at the Village Bakery - a job he has since lost. The drugs were seized and Saeed was 'sent on his way' by officers, Mr Lees said. He was also summoned to attend court via postal requisition for being in breach of his suspended sentence. The prosecution said that he had failed to comply with the order due to having missed pre-planned appointments with probation in March and April. He had also breached the GPS exclusion zone eight times and completed just two of the 30 Rehabilitation Activity Requirement hours on the order, as well as just 24 of the 110 hours of unpaid work. Andrew Jebb, defending Saeed, said the defendant was a 'very immature 18-year-old' and was 'someone with a great deal of growing up to do'. IN OTHER CRIME NEWS Mr Jebb added: "He perhaps does not fully appreciate the consequences that might flow if he doesn't fully comply with the order." He said that the GPS breaches were mostly due to taxis Saeed was travelling in for work having 'just crossed the threshold'. Sentencing Saeed, Judge Nicola Jones said that a continuation of the suspended sentence order would 'keep him away from the bus station'. He was fined £140, and a further 25 hours of unpaid work were added to the initial 110 on the order. The Judge said: "I find there are exceptional circumstances in this matter, because of your age and immaturity. But, this is the last chance you will get." She added: "Mark my words - next time you breach this order, you will go before Judge (Rhys) Rowlands who dealt with you initially and he will send you to prison."
Associated Press
24-02-2025
- Business
- Associated Press
Celltrion Receives EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra® (tocilizumab)
INCHEON, South Korea--(BUSINESS WIRE)--Feb 23, 2025-- Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma ® (CT-P47), a biosimilar referencing RoActemra ® (tocilizumab). Avtozma ® has been approved for all indications of its reference product, including moderate to severely active rheumatoid arthritis (RA), active systemic juvenile idiopathic arthritis (sJIA), polyarticular juvenile idiopathic arthritis (pJIA) and giant cell arteritis (GCA). 1 The approval further strengthens Celltrion's growing immunology portfolio. 'Today's approval of Avtozma ®, a biosimilar to RoActemra ®, marks a critical step in Celltrion's mission to provide European healthcare systems with affordable, effective solutions for immunological disorders. By leveraging our integrated operations, we strengthen the stability of supply chains and enhance collaboration with European healthcare professionals,' said Taehun Ha, Senior Vice President and Head of Europe at Celltrion. 'We are committed to delivering value-driven solutions tailored to the unique needs of the European market.' The EC approval on Avtozma ® was supported by a comprehensive data package and totality of evidence, including the results from a phase III study demonstrating biosimilarity between Avtozma ® and the reference product. The primary endpoint was met in terms of mean change from baseline in Disease Activity Score (DAS) using 28 joints (DAS28)-ESR at Week 12, and the final results supported comparability in secondary efficacy, pharmacokinetics (PK), safety and immunogenicity results between Avtozma ® and RoActemra ®. 2,3 Avtozma ® is Celltrion's twelfth biosimilar product approved by the EC, following the approval of Remsima ® (intravenous infliximab), Remsima ® SC (subcutaneous infliximab), Yuflyma ® (adalimumab), SteQeyma ® (ustekinumab), Truxima ® (rituximab), Herzuma ® (trastuzumab), Vegzelma ® (bevacizumab), Omlyclo ® (omalizumab), Eydenzelt ® (aflibercept), Stoboclo ® and Osenvelt ® (denosumab). About CT-P47 Phase III Clinical Trial 2,3 This was a Phase III, randomised, active-controlled, double-blind trial to compare the efficacy and safety of Avtozma ® (CT-P47) and RoActemra ® (tocilizumab) in patients with moderate to severely active rheumatoid arthritis (RA). Therapeutic equivalence of CT-P47 and reference tocilizumab in treating RA was demonstrated and supported by comparable and sustained efficacy results up to Week 52. CT-P47 was also well tolerated with a safety profile comparable to reference tocilizumab, and no notable safety issue was identified following the single transition from reference tocilizumab to CT-P47 compared with maintenance groups up to Week 52. About Avtozma ® (CT-P47, biosimilar tocilizumab) Avtozma ®, containing the active ingredient tocilizumab, is a recombinant humanised monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial, designed to evaluate the efficacy, pharmacokinetics, safety, and immunogenicity of Avtozma ® compared to the reference product 2,3, Avtozma ® has been approved for all indications of its reference product, including moderate to severely active rheumatoid arthritis (RA), active systemic juvenile idiopathic arthritis (sJIA), polyarticular juvenile idiopathic arthritis (pJIA) and giant cell arteritis (GCA). 1 Avtozma ® was also approved by the U.S. FDA in January 2025. About Celltrion Celltrion is a leading biopharmaceutical company that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, haematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website and stay updated with our latest news and events on our social media - LinkedIn, Instagram, X, and Facebook. FORWARD-LOOKING STATEMENT Certain information set forth in this press release contains statements related to our future business, and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. These statements may be identified by words such as 'prepares,' 'hopes to,' 'upcoming,' 'plans to,' 'aims to,' 'to be launched,' 'is preparing,' 'once gained,' 'could,' 'with the aim of,' 'may,' 'once identified,' 'will,' 'working towards,' 'is due,' 'become available,' 'has potential to,' the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. Trademarks Avtozma ® is a registered trademark of Celltrion, Inc., used under license. RoActemra ® is a registered trademark of Chugai Pharmaceutical Co., Ltd. References _______________________________ 1 European Medicines Agency Summary of Product Characteristics (SmPC), Avtozma. [Last accessed February 2025]. 2 Smolen JS et al., Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47. RMD Open. 2024;10(4), e004514. Available at: [Last accessed February 2025] 3 Gerd Burmester et al., Similar Efficacy, PK, Safety, and Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 52 Results from the Phase III Single Transition Study. Poster Presentation (abstract no. 0502). Presented at ACR 2024. Available at: [Last accessed February 2025] SOURCE: Celltrion Copyright Business Wire 2025. PUB: 02/23/2025 06:50 PM/DISC: 02/23/2025 06:51 PM
